Stopzetten van S100A1 is op zich een teleurstelling. Het betrof een onderzoek waarover weinig gesproken werd (afspraak met klant/aandeelhouder BMS).
Hoe serieus kunnen we de gerelateerde nieuwe aangekondigde samenwerkingsonderzoeken opvatten?
Nog geen persbericht van Bristol-Myers Squibb gezien over de stopzetting S100A1. Welke toekomstige positie wenst BMS in te nemen m.b.t. de eigenaarschap van uniQure. In ieder geval lijkt BMS (voortzetting samenwerking) nog dicht bij het vuur te willen blijven.
Even terug in de tijd, uit het archief het financiële deel:
The financial terms include guaranteed, near-term payments to us of at least $97 million, including an upfront payment of $50 million to be made at the closing of the transaction. The closing of the transaction is expected to occur in the second quarter of 2015 subject to Hart-Scott-Rodino clearance and customary closing conditions. An additional $15 million payment is to be received within three months of the closing for the selection of three additional collaboration targets, in addition to the S100A1 program. An initial equity investment in uniQure will be made for a number of shares that will equal 4.9% of the total number of shares outstanding following such issuance, at a purchase price of $33.84 per share, or at least $32 million in total. This investment is expected to be completed in the second quarter of 2015. BMS is also obligated to make an additional equity investment in uniQure for a number of shares that will equal 5.0% of the total number of shares outstanding following such issuance by December 31, 2015 and will be granted two warrants to acquire at its option up to an additional 10% equity interest, at a premium to market, based on additional targets being introduced into the collaboration. The parties have also agreed to enter into a supply contract, under which uniQure will undertake the manufacturing of all gene therapy products under the collaboration.
uniQure will be eligible to receive research, development and regulatory milestone payments, including up to $254 million for the lead
S100A1 therapeutic and up to $217 million for each other gene therapy product potentially developed under the collaboration, assuming designation of all targets by BMS and achievement of all milestones. uniQure is also eligible to receive target designation fees, net sales based milestone payments and tiered single to double-digit royalties on product sales.
Ordinary shares offered by us
3,000,000 ordinary shares
Ordinary shares to be outstanding immediately after this offering
21,430,066 ordinary shares
Option to purchase additional ordinary shares
We have granted the underwriters an option to purchase up to an additional 450,000 ordinary shares from us. This option is exercisable, in whole or in part, for a period of 30 days from the date of this prospectus supplement.
Use of Proceeds
We estimate that the net proceeds to us from this offering, based on an assumed offering price of $33.61, the last reported sale price of our ordinary shares on the NASDAQ Global Select Market on April 6, 2015, after deducting underwriting discounts and commissions and estimated offering expenses payable by us, will be approximately $94.0 million, or $108.2 million if the underwriters exercise their option to purchase additional shares from us in full. We intend to use the net proceeds from this offering to fund research and development to build our product platform and advance our pipeline of preclinical product candidates and for working capital and general corporate purposes.